# Repeat hepatectomy versus thermal ablation therapy for recurrent hepatocellular carcinoma: a systematic review and meta-analysis

**Authors:** Renhua Dong, Ting Zhang, Wenwu Wan, Hao Zhang

PMC · DOI: 10.3389/fonc.2024.1370390 · 2024-03-28

## TL;DR

This study compares repeat surgery and heat-based treatment for liver cancer recurrence, finding that surgery offers better survival but more complications.

## Contribution

A meta-analysis comparing survival and complications of repeat hepatectomy and thermal ablation for recurrent HCC.

## Key findings

- Repeat hepatectomy showed better overall and recurrence-free survival than thermal ablation.
- Thermal ablation resulted in fewer postoperative complications compared to repeat hepatectomy.
- No significant difference in perioperative mortality was observed between the two treatments.

## Abstract

This meta-analysis was conducted to assess the survival benefits of repeat hepatectomy (RH) and thermal ablation therapy (TAT) in managing recurrent hepatocellular carcinoma (HCC).

A comprehensive search was conducted in the PubMed, SinoMed, Embase, Cochrane Library, Medline, and Web of Science databases using relevant keywords to identify all studies published on this specific topic. Pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were estimated using a fixed-effects model.

This meta-analysis included a total of 21 studies, comprising 2580 patients with recurrent HCC, among whom 1189 underwent RH and 1394 underwent TAT. Meta-analysis results demonstrated that the RH group exhibited superior overall survival (OS) (HR=0.85, 95%CI 0.76∼0.95, P=0.004) and recurrence-free survival (RFS) (HR=0.79, 95%CI 0.7∼0.9, P<0.01) compared to the TAT group. Regarding postoperative complications, the TAT group experienced fewer complications than the RH group (OR=3.23, 95%CI 1.48∼7.07, P=0.003), while no significant difference in perioperative mortality was observed between the two groups (OR=2.11, 95%CI 0.54∼8.19, P=0.28).

The present study demonstrates that, in comparison to TAT, RH may confer superior survival benefits for patients with recurrent HCC.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Diseases:** HCC (MESH:D006528), postoperative complications (MESH:D011183)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11007030/full.md

---
Source: https://tomesphere.com/paper/PMC11007030